November 3 earnings carry USD 83.61 million estimate for Aurinia Pharmaceuticals stock
Published on 10/15/2026 at 22:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSReporting date and valuation
- MarketBeat estimates Aurinia Pharmaceuticals will report third-quarter results on November 3, 2026, with USD 83.61 million in expected revenue.
- Consensus calls for USD 0.22 in earnings per share for the third quarter of 2026.
- Aurinia Pharmaceuticals stock costs EUR 14.92 at Lang & Schwarz on October 15, 2026 at 10:26 p.m. CEST, plus 0.72 percent on Nasdaq versus the prior close of October 14, 2026.
- Aurinia Pharmaceuticals trades at a trailing P/E ratio of 7.31 as of October 15, 2026.
November 3 is the next date on Aurinia Pharmaceuticals' calendar, with MarketBeat estimating third-quarter revenue at USD 83.61 million and earnings at USD 0.22 per share. The company is listed on the Nasdaq under AUPH, and its latest euro quotation stood at EUR 14.92 at Lang & Schwarz on October 15, 2026 at 10:26 p.m. CEST, while the Nasdaq session was up 0.72 percent versus the October 14, 2026 close.
What the November estimate implies
The revenue estimate of USD 83.61 million compares with USD 73.47 million in the year-earlier quarter, an expected increase of 13.80 percent, according to MarketBeat. Its consensus earnings estimate of USD 0.22 per share is below the USD 0.23 reported for the same quarter a year earlier.
Stock position and trading frame
Aurinia Pharmaceuticals has a 52-week Nasdaq range of USD 11.30 to USD 19.25 as of October 15, 2026. The USD 16.73 home-market price is 13.09 percent below the yearly high, while the current euro quote provides the German-market view after hours.
The company reported USD 83.2 million in revenue for the second quarter of 2026, according to TickerMover. The same source lists 2026 revenue guidance of USD 315.00 million to USD 325.00 million and LUPKYNIS net product sales guidance of USD 305.00 million to USD 315.00 million.
Valuation and the next date
Aurinia Pharmaceuticals had a market capitalization of USD 2.2 billion and a trailing P/E ratio of 7.31 on October 15, 2026. The November 3, 2026 reporting date is estimated for before the Nasdaq open, with an 8:30 a.m. ET conference call, according to MarketBeat.
Comparison with peers
Aurinia Pharmaceuticals (Nasdaq, USD): plus 0.72 percent, P/E 7.31, market capitalization USD 2.2 billion.
Gilead Sciences (Nasdaq, USD): plus 2.49 percent, P/E minus 58.94, market capitalization USD 195.1 billion.
Amgen (Nasdaq, USD): plus 1.86 percent, P/E 26.98, market capitalization USD 234.7 billion.
Euro quote after hours
The German-market quotation gives Aurinia Pharmaceuticals a euro value of EUR 14.92 on October 15, 2026 at 10:26 p.m. CEST. The next scheduled company event is the estimated third-quarter report on November 3, 2026.
The further course of trading is shown by the continuously updated real-time quote of Aurinia Pharmaceuticals stock.
Aurinia Pharmaceuticals market data
- Company: Aurinia Pharmaceuticals Inc.
- ISIN: CA05156V1022
- Ticker: AUPH
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 15, 2026, 10:26 p.m. CEST): EUR 14.92
- Change on Nasdaq versus the prior close: plus 0.72 percent
- Market capitalization: USD 2.2 billion (as of October 15, 2026)
- 52-week range: USD 11.30-19.25 (as of October 15, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 3, 2026
Market context: Market report S&P 500.
